Amgen (AMGN)
(Real Time Quote from BATS)
$322.15 USD
+0.36 (0.11%)
Updated Nov 7, 2024 01:30 PM ET
3-Hold of 5 3
B Value C Growth C Momentum B VGM
Amgen (AMGN) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$335.17 | $405.00 | $200.00 | 4.16% |
Price Target
Based on short-term price targets offered by 24 analysts, the average price target for Amgen comes to $335.17. The forecasts range from a low of $200.00 to a high of $405.00. The average price target represents an increase of 4.16% from the last closing price of $321.79.
Analyst Price Targets (24)
Broker Rating
Amgen currently has an average brokerage recommendation (ABR) of 2.14 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 29 brokerage firms. The current ABR compares to an ABR of 2.15 a month ago based on 27 recommendations.
Of the 29 recommendations deriving the current ABR, 14 are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 48.28% and 3.45% of all recommendations. A month ago, Strong Buy made up 48.15%, while Buy represented 3.7%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 14 | 14 | 13 | 11 | 12 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 12 | 12 | 11 | 11 | 11 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 2 | 2 | 2 | 2 | 2 |
ABR | 2.14 | 2.14 | 2.15 | 2.24 | 2.19 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
11/1/2024 | Cowen & Co. | Yaron Werber | Strong Buy | Strong Buy |
10/31/2024 | Evercore Partners | Not Identified | Not Available | Strong Buy |
10/30/2024 | Not Identified | Not Identified | Hold | Hold |
10/17/2024 | Not Identified | Not Identified | Not Available | Strong Buy |
10/14/2024 | Truist Securities | Srikripa Devarakonda | Strong Buy | Hold |
10/4/2024 | Not Identified | Not Identified | Hold | Hold |
9/30/2024 | Goldman Sachs | Salveen Richter | Strong Buy | Strong Buy |
9/27/2024 | Cantor Fitzgerald & Co | Olivia Brayer | Not Available | Strong Buy |
9/25/2024 | Robert W. Baird & Co. | Brian P Skorney | Strong Sell | Strong Sell |
9/19/2024 | Atlantic Equities | Steven K Chesney | Strong Sell | Strong Sell |
9/16/2024 | Not Identified | Not Identified | Not Available | Strong Buy |
8/14/2024 | William Blair | Matt Phipps | Strong Buy | Strong Buy |
8/13/2024 | Daiwa America | Narumi Nakagiri | Strong Buy | Strong Buy |
8/8/2024 | UBS | Trung Huynh | Not Available | Hold |
8/7/2024 | Raymond James | Gary Nachman | Hold | Hold |
8/7/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
8/7/2024 | SVB Securities | David Risinger | Hold | Hold |
8/7/2024 | Wells Fargo Securities | Mohit Bansal | Strong Buy | Hold |
8/7/2024 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
8/6/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
6/27/2024 | Argus Research Corp. | David A Toung | Strong Buy | Strong Buy |
5/20/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
5/9/2024 | Mizuho SecuritiesUSA | Salim Syed | Hold | Hold |
5/3/2024 | BMO Capital Markets | Evan Seigerman | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.14 |
ABR (Last week) | 2.14 |
# of Recs in ABR | 29 |
Average Target Price | $335.17 |
LT Growth Rate | 5.70% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 89 of 252 |
Current Quarter EPS Est: | 4.45 |
AMGN FAQs
Amgen Inc. (AMGN) currently has an average brokerage recommendation (ABR) of 2.14 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 29 brokerage firms.
The average price target for Amgen Inc. (AMGN) is $335.17. The current on short-term price targets is based on 15 reports.
The forecasts for Amgen Inc. (AMGN) range from a low of $200 to a high of $405. The average price target represents a increase of $4.16 from the last closing price of $321.79.
The current UPSIDE for Amgen Inc. (AMGN) is 4.16%
Based on short-term price targets offered by 24 analysts, the average price target for Amgen comes to $335.17. The forecasts range from a low of $200.00 to a high of $405.00. The average price target represents an increase of 4.16% from the last closing price of $321.79.